↓ Skip to main content

Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, August 2013
Altmetric Badge

Mentioned by

facebook
1 Facebook page

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients
Published in
Journal of Experimental & Clinical Cancer Research, August 2013
DOI 10.1186/1756-9966-32-49
Pubmed ID
Authors

Patrizia Vici, Domenico Sergi, Laura Pizzuti, Luciano Mariani, Maria Grazia Arena, Maddalena Barba, Marcello Maugeri-Saccà, Cristina Vincenzoni, Enrico Vizza, Giacomo Corrado, Giancarlo Paoletti, Federica Tomao, Silverio Tomao, Diana Giannarelli, Luigi Di Lauro

Abstract

Currently, no clearly superior management strategy exists for recurrent, platinum-resistant ovarian cancer. We tested the efficacy and safety of gemcitabine combined with oxaliplatin (GEMOX) in a multicentre phase II clinical trial.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 5 26%
Other 3 16%
Student > Ph. D. Student 3 16%
Student > Postgraduate 3 16%
Student > Doctoral Student 1 5%
Other 2 11%
Unknown 2 11%
Readers by discipline Count As %
Medicine and Dentistry 8 42%
Nursing and Health Professions 2 11%
Mathematics 1 5%
Psychology 1 5%
Agricultural and Biological Sciences 1 5%
Other 2 11%
Unknown 4 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 January 2015.
All research outputs
#22,759,802
of 25,374,917 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#1,968
of 2,379 outputs
Outputs of similar age
#186,200
of 208,974 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#10
of 12 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,379 research outputs from this source. They receive a mean Attention Score of 4.8. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 208,974 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.